Combination of Talazoparib and Palbociclib as a Potent Treatment Strategy in Bladder Cancer

Combination of Talazoparib and Palbociclib as a Potent Treatment Strategy in Bladder Cancer

The use of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors represents a potent strategy for cancer therapy. Due to the complex molecular network that regulates cell cycle progression, cancer cells often acquire resistance mechanisms against these inhibitors. Previously, our group identified molecula...

Full description

Bibliographic Details
Main Authors: Florian G. Klein, Charlène Granier, Yuling Zhao, Qi Pan, Zhichao Tong, Jürgen E. Gschwend, Per Sonne Holm, Roman Nawroth
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Journal of Personalized Medicine
Subjects:
bladder cancer
combination therapy
Talazoparib
Olaparib
Palbociclib
Retinoblastoma protein
Online Access:https://www.mdpi.com/2075-4426/11/5/340

Internet

https://www.mdpi.com/2075-4426/11/5/340

Similar Items